Wiki source code of Neurodiagnoses

Version 20.1 by manuelmenendez on 2025/01/28 00:03

version	line-number	content
1.1	1	(% class="jumbotron" %)
	2	(((
	3	(% class="container" %)
	4	(((
17.1	5	= //A new tridimensional diagnostic framework for neurodegenerative diseases// =
1.1	6
19.1	7	This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
6.1	8	We aim to create a structured, interpretable, and scalable diagnostic tool.
1.1	9	)))
	10	)))
	11
	12	(% class="row" %)
	13	(((
	14	(% class="col-xs-12 col-sm-8" %)
	15	(((
6.1	16	= What is this about and what can I find here? =
1.1	17
9.1	18	== Overview ==
6.1	19
17.1	20	The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on:
6.1	21
16.1	22	* Axis 1: Etiology (genetic or other causes of diseases).
	23	* Axis 2: Molecular Markers (biomarkers).
6.1	24	* Axis 3: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
	25
20.1	26
14.1	27	[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png\|\|alt="tridimensional view of neurodegenerative diseases"]]
	28
15.1	29
6.1	30	This methodology enables:
	31
	32	* Greater precision in diagnosis.
	33	* Integration of incomplete datasets using AI-driven probabilistic modeling.
	34	* Stratification of patients for personalized treatment.
	35
9.1	36	== Diagnostic Axes ==
6.1	37
	38	* (((
	39	Axis 1: Etiology
	40
	41	* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
	42	* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
	43	* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
	44	)))
	45	* (((
	46	Axis 2: Molecular Markers
	47
	48	* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
	49	* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
	50	* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
	51	)))
	52	* (((
	53	Axis 3: Neuroanatomoclinical
	54
	55	* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
	56	* //Examples//: Hippocampal atrophy correlating with memory deficits.
	57	* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
	58	)))
	59
9.1	60	== Applications ==
6.1	61
	62	This system enhances:
	63
7.2	64	* Research: By stratifying patients, reduces cohort heterogeneity in clinical trials.
6.1	65	* Clinical Practice: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
	66
5.1	67	== Who has access? ==
1.1	68
4.2	69	We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
4.4	70
10.1	71	== How to Contribute ==
4.4	72
	73	* Access the `/docs` folder for guidelines.
	74	* Use `/code` for the latest AI pipelines.
	75	* Share feedback and ideas in the wiki discussion pages.
5.1	76
10.1	77	== Key Objectives ==
5.1	78
	79	* Develop interpretable AI models for diagnosis and progression tracking.
	80	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
	81	* Foster collaboration among neuroscientists, AI researchers, and clinicians.
1.1	82	)))
	83
	84
	85	(% class="col-xs-12 col-sm-4" %)
	86	(((
	87	{{box title="Contents"}}
	88	{{toc/}}
	89	{{/box}}
	90
10.1	91	== Main contents ==
4.4	92
5.1	93	* `/docs`: Documentation and contribution guidelines.
	94	* `/code`: Machine learning pipelines and scripts.
	95	* `/data`: Sample datasets for testing.
	96	* `/outputs`: Generated models, visualizations, and reports.
1.1	97	)))
	98	)))